At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 408 enrolled
Drug / intervention
Esomeprazole 40 mgdrug
Likely dose
Esomeprazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis
In Brief
A Phase 4 clinical trial evaluating Esomeprazole 40 mg for Erosive Esophagitis. Completed, enrolled 408 participants across 1 site.
Detailed Summary
To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErosive Esophagitis
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2013
Primary CompletionJun 2016
TodayJul 2026
First PostedJun 11, 2013
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 13.1 years ago
Interventions
Esomeprazole 40 mgdrug
Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis